- Home
- ANVS vs QNCX Comparison
ANVS vs QNCX Comparison
Compare ANVS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- QNCX
- Stock Information
- Founded
- ANVS 2008
- QNCX 2012
- Country
- ANVS United States
- QNCX United States
- Employees
- ANVS N/A
- QNCX N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANVS Health Care
- QNCX Health Care
- Exchange
- ANVS Nasdaq
- QNCX Nasdaq
- Market Cap
- ANVS 44.6M
- QNCX 47.7M
- IPO Year
- ANVS 2020
- QNCX 2019
- Fundamental
- Price
- ANVS $2.36
- QNCX $1.64
- Analyst Decision
- ANVS Strong Buy
- QNCX Strong Buy
- Analyst Count
- ANVS 4
- QNCX 5
- Target Price
- ANVS $18.00
- QNCX $8.00
- AVG Volume (30 Days)
- ANVS 485.7K
- QNCX 353.3K
- Earning Date
- ANVS 08-14-2025
- QNCX 08-12-2025
- Dividend Yield
- ANVS N/A
- QNCX N/A
- EPS Growth
- ANVS N/A
- QNCX N/A
- EPS
- ANVS N/A
- QNCX N/A
- Revenue
- ANVS N/A
- QNCX N/A
- Revenue This Year
- ANVS N/A
- QNCX N/A
- Revenue Next Year
- ANVS N/A
- QNCX N/A
- P/E Ratio
- ANVS N/A
- QNCX N/A
- Revenue Growth
- ANVS N/A
- QNCX N/A
- 52 Week Low
- ANVS $1.11
- QNCX $0.51
- 52 Week High
- ANVS $17.88
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- ANVS 48.29
- QNCX 64.95
- Support Level
- ANVS $2.05
- QNCX $1.48
- Resistance Level
- ANVS $3.18
- QNCX $1.68
- Average True Range (ATR)
- ANVS 0.26
- QNCX 0.14
- MACD
- ANVS -0.08
- QNCX 0.02
- Stochastic Oscillator
- ANVS 27.43
- QNCX 85.71
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.